HHS to Fund Domestic Production of Bavarian Nordic’s Jynneos Vaccine

HHS has granted Grand River Aseptic Manufacturing $11.2 million to help boost the company’s fill and finish operations for the Bavarian Nordic monkeypox vaccine.

The funds will enable the company to buy additional equipment to manufacture the Jynneos vaccine at its site in Grand Rapids, Mich., and will accelerate production, HHS said.

Bavarian Nordic announced earlier this month that it had begun a technology transfer to the U.S. contract manufacturer. But manufacturing can’t begin until that transfer is completed.

The Bavarian Nordic vaccine is indicated for prevention of monkeypox infections in adults 18 years and older who are at high risk.